understanding the us fda drug review and approval process n.
Skip this Video
Loading SlideShow in 5 Seconds..
Understanding the US FDA Drug Review and Approval Process PowerPoint Presentation
Download Presentation
Understanding the US FDA Drug Review and Approval Process

Loading in 2 Seconds...

play fullscreen
1 / 5

Understanding the US FDA Drug Review and Approval Process - PowerPoint PPT Presentation

  • Uploaded on

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Understanding the US FDA Drug Review and Approval Process' - GRCTS

Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
understanding the us fda drug review and approval process

Understanding the US FDA Drug Review and Approval Process

Speaker: David Lim| Date: 15th June 2016 2016 2016 | 10:00 AM PST | 01:00 PM EST

Contact Us : Email: support@grcts.com | Tel: +1-248-233-2049



The FDA’s Center for Drug Evaluation and Research (CDER) is responsible for reviewing and approving both prescription and nonprescription or over-the-counter (OTC) drugs.

To introduce a new drug product into the U.S. market, some firms submit a new drug application (NDA) to the US FDA/CDER.

The firms are responsible for testing a drug and for submitting evidence that the drug is safe and effective.

This webinar is intended to help you better understand FDA’s drug review and approval process. The FDA’s recent approvals of novel drugs will also be discussed.

areas covered in the session


  • FDA Guidance's
  • Definitions
  • Drug Development
  • FDA Drug Review and Approval
  • Common Mistakes
  • Critical Considerations
  • Enforcement Actions
  • Recent FDA Approvals
  • PASS-IT Recommendations

Areas Covered in the Session:

who will benefit


  • VPs
  • Compliance Officers
  • Attorneys
  • Regulatory Affairs
  • Clinical Affairs
  • Quality Assurance
  • R&D

Who will benefit:

instructor profile

Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor (www.RegulatoryDoctor.us). As a leading industry speaker, Dr. Lim frequently presents global regulatory and quality compliance topics in various forums and meetings. Recently, Dr. Lim developed 510(k) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past eight years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009.

Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author and speaker. Dr. Lim leads and directs all research projects including pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor. Dr. Lim currently serves as a member of the Advisory Board for Inspection Insider published by FDA News.

Instructor Profile :